缬沙坦对伴有或不伴有2型糖尿病的肥胖非高血压受试者胰岛素敏感性的急性影响。

Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.

作者信息

Luzio S D, Dunseath G, Owens D R

机构信息

Diabetes Research Unit, Llandough Hospital, Penlan Road, Penarth, S. Glam. CF64 2XX, Wales, UK.

出版信息

Horm Metab Res. 2002 May;34(5):271-4. doi: 10.1055/s-2002-32142.

DOI:10.1055/s-2002-32142

PMID:12063642

Abstract

BACKGROUND

Two studies were designed to determine whether a single dose (80 mg) of the angiotensin II receptor blocker (ARB), valsartan, alters insulin sensitivity in obese, non-hypertensive subjects with and without Type 2 diabetes.

METHODS

Insulin sensitivity (S(I)), glucose effectiveness (S(G)), and acute insulin response (AIR(0-10 min)) were measured by means of a 3-hour insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT) before and after a single dose of valsartan. Study 1: obese, normotensive non-diabetic male subjects (n = 12), mean (SD) age 37.2 +/- 11.2 years, BMI 32.8 +/- 6.8 kg/m (2); Study 2: obese, normotensive Type 2 diabetic patients (n = 12), mean age 55.7 +/- 6.9 years, BMI 35.0 +/- 6.8 kg/m (2)/l. Both studies were randomised, double-blind, placebo-controlled, single-dose crossover group studies involving subjects in two study days, two weeks apart. After fasting samples were taken, a 300 mg/kg iv glucose bolus was injected at 0 min, and 0.05 U/kg iv insulin was given 20 min later. Blood samples for analysis of glucose and insulin were taken throughout the 3-hour study period.

RESULTS

Study 1 (non-diabetic subjects) S(I) 2.81 vs. 2.63 x 10 (-4) min (-1) per microU/ml (p = 0.54), S(G) 0.020 vs. 0.020 min (-1) (p = 0.90), AIR(0-10) min 3305 vs. 3450 microU/min/ml (p = 0.71); Study 2 (patients with type 2 diabetes) S(I) 0.59 vs. 0.85 x 10 (-4) min (-1) per microU/ml (p = 0.15), S(G) 0.013 vs. 0.014 min (-1) (p = 0.71), AIR(0-10) min 65 vs. 119 microU/min/ml (p = 0.14), placebo vs. valsartan, respectively.

CONCLUSION

In obese, non-hypertensive non-diabetic and Type 2 diabetic subjects a single dose of valsartan does not alter insulin sensitivity.

摘要

背景

两项研究旨在确定单剂量（80毫克）的血管紧张素II受体阻滞剂（ARB）缬沙坦是否会改变肥胖、非高血压且患有或未患2型糖尿病的受试者的胰岛素敏感性。

方法

通过3小时胰岛素改良频繁采样静脉葡萄糖耐量试验（FSIVGTT）在单剂量缬沙坦给药前后测量胰岛素敏感性（S(I)）、葡萄糖效能（S(G)）和急性胰岛素反应（AIR(0 - 10分钟)）。研究1：肥胖、血压正常的非糖尿病男性受试者（n = 12），平均（标准差）年龄37.2 ± 11.2岁，BMI 32.8 ± 6.8 kg/m²；研究2：肥胖、血压正常的2型糖尿病患者（n = 12），平均年龄55.7 ± 6.9岁，BMI 35.0 ± 6.8 kg/m²。两项研究均为随机、双盲、安慰剂对照、单剂量交叉组研究，受试者在两个研究日参与，间隔两周。在采集空腹样本后，于0分钟静脉注射300毫克/千克葡萄糖推注，20分钟后静脉注射0.05单位/千克胰岛素。在整个3小时研究期间采集用于分析葡萄糖和胰岛素的血样。

结果

研究1（非糖尿病受试者）S(I) 2.81对2.63×10⁻⁴分钟⁻¹/微单位/毫升（p = 0.54），S(G) 0.020对0.020分钟⁻¹（p = 0.90），AIR(0 - 10)分钟3305对3450微单位/分钟/毫升（p = 0.71）；研究2（2型糖尿病患者）S(I) 0.59对0.85×10⁻⁴分钟⁻¹/微单位/毫升（p = 0.15），S(G) 0.013对0.014分钟⁻¹（p = 0.71），AIR(0 - 10)分钟65对119微单位/分钟/毫升（p = 0.14），分别为安慰剂对缬沙坦。